Relationship between Acute-Phase Symptoms and Immunoglobulin G Seropositivity up to Eight Months after COVID-19COVID-19 이후 최대 8개월까지 급성기 증상과 면역글로불린 G 혈청양성 간의 관계Article Published on 2022-05-262022-09-11 Journal: Medicina [Category] MERS, 진단, 치료제, [키워드] acute phase adjusted analyzed Anosmia antibody Antibody Response Antibody responses chance classification clinical manifestation COVID-19 creating cross-sectional cross-sectional study dependence determinants Dyspnea effective HCW HCWs healthcare worker highest IgG Immunoglobulin Immunoglobulin G knowledge Logistic regression material Month multiple logistic regression Occurrence Odds ratio post-symptom onset proportion relationship responses S1 and S2 serology testing seronegative Seropositivity significantly increased Spike protein Surveillance Symptom symptom onset tested the spike protein was increased [DOI] 10.3390/medicina58060708 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVacCoronaVac을 투여받은 성인에서 피내 경로를 통한 AZD1222의 추가 투여 후 면역원성 및 반응성Article Published on 2022-05-262022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 95%CI administration anti-S anti-SARS-CoV-2 IgG Anti-spike antibody Antibody Response Antibody responses Antibody titer AstraZeneca AZD1222 Blister booster booster dose ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine cohort study common completion CoronaVac CoronaVac vaccine COVID-19 vaccine COVID-19 vaccines delta variant determine dose Endpoint Erythema evaluated geometric geometric mean geometric mean ratios GMRs healthy IgG immunogenicity Immunoglobulin Immunoglobulin G immunologic response injection Intradermal Local median age neutralization test Neutralizing antibodies neutralizing antibody Neutralizing antibody titer occurred participant participated primary endpoint proportion prospective cohort study RBD IgG reactogenicity recipient reported resource SARS-CoV-2 vaccine surrogate virus neutralization test sVNT systemic reactogenicity variant Viral Virus neutralization was collected wild type [DOI] 10.1016/j.vaccine.2022.04.067 PMC 바로가기 [Article Type] Article
Risk of COVID-19 re-infection and its predictors (CORES): protocol for a community-based longitudinal cohort study in Vellore, IndiaCOVID-19 재감염 및 그 예측인자(CORES)의 위험: 인도 벨로르에서 지역사회 기반 종단 코호트 연구를 위한 프로토콜Article Published on 2022-05-242022-09-11 Journal: BMJ Open [Category] COVID19(2023년), SARS, 치료기술, [키워드] analysed antibody Antibody responses approved attack rate B cell memory baseline blood sample Blood samples collected college Community community setting COVID-19 defined detect elicited Ethics evaluated Evidence evidence of expected Factor General population group Health policy healthy immune response immune responses immunology incidence India Infection institutional review board IRB Kinetics Longevity longitudinal cohort study natural infection positive Post-infection predictor presence of antibody Primary infection protocol public health Re-infection recruit registration number registry responses reverse transcription-PCR risk risk factor Risk factors RT-PCR Saliva saliva samples SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 infections SARS-CoV-2 spike protein seronegative seropositive Seropositivity Seroprevalence seroprevalence survey Spike protein T cell T cell memory tested understanding vaccination Vaccination Status Weekly [DOI] 10.1136/bmjopen-2021-059869 PMC 바로가기 [Article Type] Article
Development of SARS-CoV-2 variant protein microarray for profiling humoral immunity in vaccinated subjects백신 접종 대상체의 체액성 면역 프로파일링을 위한 SARS-CoV-2 변이 단백질 마이크로어레이 개발Article Published on 2022-05-152022-09-11 Journal: Biosensors & bioelectronics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 anti-spike antibody antibody Antibody responses AZD1222 B.1.1.7 B.1.351 B.1.617 B.1.617.1 B.1.617.2 binding ChAdOx1 chimeric collected correlated D614G demonstrated develop development domain Drug development Extracellular globe host receptor Humoral immunity Humoral response humoral responses IgA IgG IgM isotype IgM isotypes immune inhibiting Microarray MONITOR mRNA-1273 mutant neutralization neutralizing activities Neutralizing activity neutralizing antibody P.1 platform Protein protein microarray Research SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants serology serum spike variants subject the antibody response vaccinated individual vaccination Vaccine Vaccines variant variants variants of concern Virus neutralization wild-type [DOI] 10.1016/j.bios.2022.114067 PMC 바로가기 [Article Type] Article
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primatesINO-4800 및 INO-4802를 사용한 프라임-부스트 백신 요법은 비인간 영장류에서 SARS-CoV-2에 대한 면역 반응을 증대 및 확대합니다.Article Published on 2022-05-092022-09-11 Journal: Vaccine [Category] Coronavirus, COVID19(2023년), SARS, 변종, 비임상, [키워드] ACE2 Antibody Response Antibody responses blocking activity Booster vaccine booster vaccines characterized clinical evaluation COVID-19 DNA DNA vaccine Electroporation evaluated expansion homologous or heterologous immune evasion immune response Immunity immunogenicity INO-4800 Intradermal macaque natural infection Neutralizing pandemic portion question regimen regimens rhesus macaque rhesus macaques SARS-CoV-2 SARS-CoV-2 sequence SARS-CoV-2 variant SARS-CoV-2 variants shifting Strains Support T cell T cells These data Transmissibility vaccination Vaccine variant variants of concern wild-type SARS-CoV-2 Wuhan-Hu-1 [DOI] 10.1016/j.vaccine.2022.03.060 PMC 바로가기 [Article Type] Article
Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2SARS-CoV-2에 대한 교차 반응성 점막 및 전신 항체 반응을 위한 열안정성 소단위 백신의 비강내 전달Article Published on 2022-05-032022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 addition Against Alpha angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anti-RBD Anti-RBD antibody antibody Antibody Response Antibody responses Antibody titer Antibody titers approved Beta binding binding domain Breakthrough infection breakthrough infections chitosan circulation COVID-19 COVID-19 vaccines CpG cross-reactive delivery Delta variants domain Efficacy effort enzyme exclusion FIVE genetic material help Hesitancy IgA antibodies IgG1 IgG2a IL-12 Immunity immunization IMPROVE induce inhibited interleukin interleukin-12 intranasal intranasal vaccination intranasally isotype Laboratory mice mucosal mucosal immunity mutant oligonucleotide polypeptide Prevent PROTECT RBD RBD-specific antibodies RBD-specific antibody receptor Receptor binding domain receptor binding domain (RBD) reduce respiratory respiratory viruses response responses room temperature SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants specific antibodies stability subcutaneous vaccination subunit Subunit vaccine systemic temperature the vaccine thermostable upper respiratory tract vaccination Vaccine Vaccine development Vaccine hesitancy vaccine platform variants virus [DOI] 10.3389/fimmu.2022.858904 PMC 바로가기 [Article Type] Article
Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis경증 COVID-19 이후 최대 1년까지 SARS-CoV-2 WT 및 변이체에 대한 B 세포 반응의 적합성 - 종합 분석Article Published on 2022-05-022022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Affinity maturation All participants Alpha Anti-RBD antibodies antibodies antibody Antibody Response Antibody responses Antibody titer Antibody titers Antigen antigen-specific memory B cells assays avidity B-cell binding binding antibodies binding antibody Comprehensive correlated COVID-19 declined Delta delta variant domain ELISA ELISPOT evaluate fitness Gamma IgA IgG memory B memory B cell memory B cells memory B-cell Mild N protein neutralization Neutralizing Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers Neutralizing titer neutralizing titers nucleocapsid participant plasmablast plasmablast responses plasmablasts post infection predicted Protein remained response SARS-CoV-2 SARS-CoV-2 specific memory B cells SARS-CoV-2 WT significantly increased symptomatic thiocyanate titers variant variants variants of concern waned were assessed were measured wild-type Year [DOI] 10.3389/fimmu.2022.841009 PMC 바로가기 [Article Type] Article
Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects의료 종사자 및 노인 대상에서 세 번째 mRNA 백신 접종 후 SARS-CoV-2 Omicron 변이체에 대한 중화 항체Article Published on 2022-05-012022-09-11 Journal: European Journal of Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] administration age antibody Antibody responses B.1.1.529 Beta booster booster vaccination Breakthrough infection breakthrough infections collected Concentration Coronavirus disease 2019 COVID-19 cross-protective cross-reactive Delta detectable dose expected HCW HCWs Health care Health care worker health care workers IgG IgG antibody mRNA vaccination mRNA vaccine Mutation NAb NAb titer NAb titers NAbs neutralization Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody nursing home omicron Postinfection raised reduced remained SARS-CoV-2 severe COVID-19 significantly Spike protein subject subjects subsequent the antibody response the spike protein vaccination vaccine dose variant variants variants of concern WT virus [DOI] 10.1002/eji.202149785 PMC 바로가기 [Article Type] Article
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease (RESCUE)면역매개염증질환(RESCUE)에서 DMARD 치료를 일시적으로 중단한 후 COVID-19 ChAdOx1nCov-19 및 BNT162b 백신에 대한 항체 반응Randomized Controlled Trial Published on 2022-05-012022-09-11 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제, [키워드] Adult patients Antibody Response Antibody responses antirheumatic agents AstraZeneca AZ vaccine baseline biologic BNT162b Control control group control groups controls COVID-19 csDMARD dose Final first and second dose first dose first vaccination group groups IgG Immune-mediated immunogenicity inflammatory disease Messenger RNA multicentre not significantly different Patient Pfizer Protein randomised randomised controlled trial registration number response S1/S2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV2 second dose second vaccination Seroconversion seroconversion rate seroconversion rates significantly lower the antibody response the mean therapy titre titres U/mL vaccination Vaccine were measured [DOI] 10.1136/rmdopen-2022-002301 PMC 바로가기 [Article Type] Randomized Controlled Trial
COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination완전한 백신 접종 후 형질 세포 이상증 환자의 COVID-19 백신 반응Article Published on 2022-05-012022-09-11 Journal: Clinical lymphoma, myeloma & leukemia [Category] MERS, 진단, 치료법, [키워드] adenoviral vector vaccine Administered age anti-CD38 anti-spike antibodies anti-spike antibody antibody Antibody Response Antibody responses Antibody testing Cell clinical history Complete consecutive patient consecutive patients COVID-19 COVID-19 vaccination detectable drug therapy dyscrasia evaluated Evidence evidence of examined functional heterologous mRNA vaccine Hypogammaglobulinemia Immunocompromised increased risk Infection IVIG Johnson & Johnson Johnson & Johnson management Moderna monoclonal antibody monoclonal antibody therapy mRNA vaccine Multiple Multiple myeloma Multivariate analysis negatively affected nucleocapsid Patient plasma Plasma cell Plasma Cell Dyscrasias Quantitative receiving response responses Roche SARS-CoV-2 second dose serologic Serologic response spike Spike antibody detection tested the timing therapy Treatment vaccination Vaccine Vaccine boosters. Vaccines were excluded were measured [DOI] 10.1016/j.clml.2021.11.001 PMC 바로가기 [Article Type] Article